New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - alanylglutamine 200 mg/ml;  ;   - concentrate for infusion - 200 mg/ml - active: alanylglutamine 200 mg/ml     excipient: nitrogen water for injection - dipeptiven® is indicated as part of a clinical nutrition regimen in patients in hypercatabolic and/or hypermetabolic states. it should be given together with parenteral or enteral nutrition or a combination of both.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 16 g/l; glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glutamine, qty 20 g); histidine, quantity: 6.8 g/l; methionine, quantity: 5.6 g/l; tryptophan, quantity: 1.9 g/l; threonine, quantity: 5.6 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: glycine, qty 10.27 g; equivalent: lysine, qty 9 g); valine, quantity: 7.3 g/l; arginine, quantity: 11.3 g/l; glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); serine, - injection, intravenous infusion - excipient ingredients: water for injections; citric acid - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - proline, quantity: 6.8 g/l; isoleucine, quantity: 5.6 g/l; methionine, quantity: 5.6 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g; equivalent: glycine, qty 10.27 g); serine, quantity: 4.5 g/l; glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glycine, qty 10.27 g; equivalent: glutamine, qty 20 g); alanine, quantity: 16 g/l; histidine, quantity: 6.8 g/l; glutamic acid, quantity: 5.6 g/l; tryptophan, quantity: 1.9 g/l; leucine, quantity: 7.9 g/l; valine, quantity: 7.3 g/l; - injection, intravenous infusion - excipient ingredients: citric acid; water for injections - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); histidine, quantity: 6.8 g/l; alanine, quantity: 16 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g; equivalent: glycine, qty 10.27 g); glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glutamine, qty 20 g; equivalent: glycine, qty 10.27 g); glutamic acid, quantity: 5.6 g/l; phenylalanine, quantity: 5.85 g/l; valine, quantity: 7.3 g/l; leucine, quantity: 7.9 g/l; - injection, intravenous infusion - excipient ingredients: citric acid; water for injections - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - alanine 16 g/l;  ;  ;  ; arginine 11.3 g/l;  ;  ; aspartic acid 3.4 g/l;  ;  ; glutamic acid 5.6 g/l;  ;  ; glycyl-l-glutamine 30.27 g/l;  ; glycyl-l-tyrosine 3.45 g/l; histidine 6.8 g/l;  ;  ; isoleucine 5.6 g/l;  ;  ;  ; leucine 7.9 g/l;  ;  ;  ; lysine acetate 12.7 g/l;  ;  ;  ; methionine 5.6 g/l;  ; phenylalanine 5.85 g/l;  ;  ;  ;  ; proline 6.8 g/l;  ; serine 4.5 g/l;  ;  ;  ; threonine 5.6 g/l;  ;  ;  ; tryptophan 1.9 g/l;  ;  ; valine 7.3 g/l;  ;   - solution for infusion - 134 g/l - active: alanine 16 g/l       arginine 11.3 g/l     aspartic acid 3.4 g/l     glutamic acid 5.6 g/l     glycyl-l-glutamine 30.27 g/l   glycyl-l-tyrosine 3.45 g/l histidine 6.8 g/l     isoleucine 5.6 g/l       leucine 7.9 g/l       lysine acetate 12.7 g/l       methionine 5.6 g/l   phenylalanine 5.85 g/l         proline 6.8 g/l   serine 4.5 g/l       threonine 5.6 g/l       tryptophan 1.9 g/l     valine 7.3 g/l     excipient: citric acid monohydrate water for injection - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate to severe catabolic status.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty limited - phenylalanine; tryptophan; alanine; glycylglutamine monohydrate; valine; aspartic acid; serine; glutamic acid; glycyltyrosine dihydrate; histidine; leucine; isoleucine; methionine; lysine acetate; proline; threonine; arginine -

New Zealand - English - Medsafe (Medicines Safety Authority)

orpharma nz limited - sodium phenylbutyrate 84 g equivalent to 483 mg of sodium phenylbutyrate per gram of granules;  ;   - oral granules - 483 mg - active: sodium phenylbutyrate 84 g equivalent to 483 mg of sodium phenylbutyrate per gram of granules     excipient: ethylcellulose hypromellose macrogol 1500 povidone sugar spheres - pheburane is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. pheburane should be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, and protein-free calorie supplements). pheburane is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy. geriatrics (> 65 years of age): pheburane has not been studied in the geriatric population.

Australia - English - Department of Health (Therapeutic Goods Administration)

orpharma pty ltd - sodium phenylbutyrate, quantity: 483 mg/g - granules - excipient ingredients: povidone; ethylcellulose; hypromellose; macrogol 1500; sucrose; hydrolysed maize starch - pheburane (sodium phenylbutyrate) is indicated for the management of hyperammonaemia associated with urea cycle disorders. pheburane? should be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, and protein-free calorie supplements)

Canada - English - Health Canada

medunik canada - sodium phenylbutyrate - granules - 483mg - sodium phenylbutyrate 483mg